Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.61 |
| ▸ | LTA4H | P09960 | 1/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3206091 | 0.84 | KMT2A (0.68) | KDM4EHRH3LTA4HLMNAMAPK1 | |
| SCHEMBL264157 | 0.84 | LTA4H (0.81) | KDM4ELTA4HLMNAMAPK1HTT | |
| SCHEMBL3216190 | 0.82 | LTA4H (0.79) | KDM4EHRH3LTA4HLMNAMAPK1 | |
| SCHEMBL3209561 | 0.82 | LTA4H (0.79) | KDM4EHRH3LTA4HLMNAMAPK1 | |
| SCHEMBL3866360 | 0.82 | SIGMAR1 (0.71) | KDM4EHRH3LTA4HSIGMAR1KMT2A | |
| SCHEMBL5388793 | 0.82 | HRH3 (0.71) | KDM4EHRH3LTA4HSIGMAR1LMNA | |
| Hydrochloric Acid SCHEMBL3859180 | 0.81 | SIGMAR1 (0.74) | KDM4EHRH3LTA4HSIGMAR1KMT2A | |
| SCHEMBL7397402 | 0.81 | TMEM97 (0.76) | LTA4HSIGMAR1MEN1KMT2A | |
| SCHEMBL2561445 | 0.80 | KDM4E (0.62) | KDM4EHRH3SIGMAR1LMNAMAPK1 | |
| SCHEMBL14320388 | 0.80 | LTA4H (0.63) | KDM4EHRH3LTA4HLMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048891-A1 | METASUBSTITUTED THIAZOLIDINONES, THEIR MANUFACTURE AND USE AS A DRUG | SCHULZE KLAUSE | 2010-02-25 | — | — | US | disclosed |
| US-20100048891-A1 | METASUBSTITUTED THIAZOLIDINONES, THEIR MANUFACTURE AND USE AS A DRUG | SCHULZE KLAUSE | 2010-02-25 | — | — | US | disclosed |
| US-20100048891-A1 | METASUBSTITUTED THIAZOLIDINONES, THEIR MANUFACTURE AND USE AS A DRUG | SCHULZE KLAUSE | 2010-02-25 | — | — | US | disclosed |
| US-20070015759-A1 | Metasubstituted thiazolidinones, their manufacture and use as a drug | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | US | disclosed |
| US-20070015759-A1 | Metasubstituted thiazolidinones, their manufacture and use as a drug | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048891-A1 | METASUBSTITUTED THIAZOLIDINONES, THEIR MANUFACTURE AND USE AS A DRUG | PLK2, PDXK, PLK4 | KDM4E 3035/4885HRH3 4815/4885LTA4H 2174/4885 |
| US-20070015759-A1 | Metasubstituted thiazolidinones, their manufacture and use as a drug | PLK4, PDXK, PLK2 | KDM4E 2470/4885HRH3 4823/4885LTA4H 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.